Quoin Pharmaceuticals to Sponsor 2024 FIRST National Conference

ASHBURN, Va., June 25, 2024 -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a clinical-stage specialty pharmaceutical company dedicated to rare and orphan diseases, has announced its involvement as a Bronze Sponsor at the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 national conference in Albuquerque, New Mexico from June 28-30, 2024.

The biennial event spans three days and serves as a crucial gathering for individuals seeking information about ichthyosis and other skin disorders. The conference facilitates networking and consultation opportunities among members of the Foundation, their families, and leading medical professionals.

Denise Carter, Chief Operating Officer of Quoin, expressed pride in sponsoring the 2024 FIRST national conference. She highlighted the significance of the network in supporting individuals and families affected by rare diseases. Carter emphasized Quoin's commitment to raising awareness, offering support to patients and families, and developing treatments for these conditions. She underscored the company's focus on delivering a safe and effective treatment for Netherton Syndrome as quickly as possible.

As a Bronze Sponsor, Quoin will also support the conference’s celebration dinner scheduled for June 29, 2024. 

Quoin Pharmaceuticals is actively engaged in two clinical trials evaluating QRX003, a topical lotion aimed at treating Netherton Syndrome. 

About The Foundation for Ichthyosis & Related Skin Types, Inc.® (FIRST):
FIRST is the sole national non-profit organization in the United States dedicated to families affected by ichthyosis. The foundation disseminates information through its website, printed publications, and the Ichthyosis Focus newsletter. It organizes a national conference every two years and provides patient support forums, enabling families to connect and consult with medical specialists.

About Quoin Pharmaceuticals Ltd.:
Quoin Pharmaceuticals Ltd. is focused on developing and commercializing therapeutic products for rare and orphan diseases. The company is committed to addressing unmet medical needs within this patient population. Quoin's development pipeline includes four products designed to treat various rare and orphan conditions, such as Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, and Epidermolysis Bullosa.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!